Tokyo/Works/Assay0
From 2007.igem.org
(→Samples:) |
(→Samples:) |
||
Line 20: | Line 20: | ||
<br>5-2. pBR322 TetR + [LacI promoter – GFP] (Neg. con. check) (AHL-) | <br>5-2. pBR322 TetR + [LacI promoter – GFP] (Neg. con. check) (AHL-) | ||
- | <br>*[Lux lac hybrid promoter – GFP] is A-4 with the new lux lac hybrid promoter replacing pluxR. | + | <br>*[Lux lac hybrid promoter – GFP] is A-4 (BBa_J54140) with the new lux lac hybrid promoter replacing pluxR. |
<br>'''Repressor LacI expression:''' | <br>'''Repressor LacI expression:''' |
Revision as of 07:07, 26 October 2007
Works top 0. Hybrid promoter 1. Formulation 2. Assay1 3. Simulation 4. Assay2 5. Future works
Assay0
Purpose 1:
To check if LacI hybrid promoter is activated by AHL and repressed by LacI.
Purpose 2:
To obtain parameters of LacI hybrid promoter for computational simulation.
Samples:
1-1. pTrc99A + [Lux lac hybrid promoter – GFP] (LacI+) (AHL+)
1-2. pTrc99A + [Lux lac hybrid promoter – GFP] (LacI+) (AHL-)
2-1. pBR322 TetR + [Lux lac hybrid promoter – GFP] (lacI-) (AHL+)
2-2. pBR322 TetR + [Lux lac hybrid promoter – GFP] (lacI-) (AHL-)
3-1. pTrc99A + [placQI – GFP] (placQI is constitutive promoter) (Pos. con.) (AHL+)
3-2. pTrc99A + [placQI – GFP] (placQI is constitutive promoter) (Pos. con.) (AHL-)
4-1. pTrc99A + [LacI promoter – GFP] (Neg. con.) (AHL+)
4-2. pTrc99A + [LacI promoter – GFP] (Neg. con.) (AHL-)
5-1. pBR322 TetR + [LacI promoter – GFP] (Neg. con. check) (AHL+)
5-2. pBR322 TetR + [LacI promoter – GFP] (Neg. con. check) (AHL-)
*[Lux lac hybrid promoter – GFP] is A-4 (BBa_J54140) with the new lux lac hybrid promoter replacing pluxR.
Repressor LacI expression:
pTrc99A expresses LacI
pBR322 TetR does NOT express LacI
Antibiotics resistance:
pTrc99A gives ampicillin-resistance
pBR322 TetR gives ampicillin-resistance
[LacI hybrid promoter – GFP] gives kanamicin-resistance
[placQI – GFP] gives kanamicin-resistance
Procedure:
Results and Conclusion
The newly devised hybrid promoter is activated by AHL and repressed by LacI.
The result is shown in Fig.1 and the characteristics of our hybrid promoter is summarized in Fig. 2.
(1) In the absence of AHL,
fluorescence was as low as that of the negative control, indicating that AHL is necessary to activate this hybrid promoter.
(2) In the presence of AHL,
Fluorescence was the strongest in the absence of LacI, though slightly decreased by IPTG addition.
In the presence of LacI, IPTG addition increased fluorescence up to a quarter of that in the absence of LacI; while, its fluorescence remained the same as that of the negative control in the absence of IPTG. Since it is known that IPTG inhibits repression of LacI, this result indicates that it is LacI that actually represses the hybrid promoter.
Those results indicate that our newly devised hybrid promoter needs AHL for its activation and is repressed by LacI regardless of the presence or absence of AHL. The hybrid promoter is released from LacI repression by IPTG, and activated if there are enough AHL.
Thus, this hybrid promoter is activated
-strongly in the absence of LacI and in the presence of AHL
-moderately in the presence of LacI and IPTG, and in the presence of AHL.